Zydus Lifesciences today said it has received approval from the US health regulator to market a generic product which is used to treat myxedema coma.
The company has received the final approval for Levothyroxine Sodium for Injection in strength of 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the US Food and Drug Administration (USFDA), the drug firm said in a statement.
Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma.
Zydus said the drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara (India).
Shares of the company were trading 0.19 per cent up at Rs 483.20 apiece on the BSE.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
from NDTV Profit-Latest https://ift.tt/9RESn5W
No comments: